GlassScriptPhysician profile
Steven D Mcnabb
NPI 1902803893
$768.81
in general payments reported to CMS, 2019-2025
14 companies · $117 in 2025
The $117 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $49.87 · 2021: $57.33 · 2022: $103 · 2023: $178 · 2024: $148 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $219.63 | 2019-2025 | |
| Corium, LLC | $106.27 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $78.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $69.93 | 2020-2023 | Vaxneuvance, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $59.38 | 2024 | |
| Tris Pharma INC | $46.75 | 2020-2023 | Dyanavel Xr |
| Ultragenyx Pharmaceutical INC. | $41.07 | 2023-2024 | Crysvita |
| Glaxosmithkline, LLC. | $40.55 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $30.92 | 2024 | Qelbree |
| Phadia US INC. | $19.77 | 2022 | |
| Genentech USA, INC. | $15.87 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.01 | 2025 | Jornay Pm |
| Sobi, INC | $13.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mcnabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.